Benjamin Neumann, a virologist at A&M University – Texarkana, Texas, said the chances of immunizing people against the epidemic are not certain as no fully effective vaccine has yet been found for any Corona virus.
“There will be many experiments and many mistakes, but we have many options.”
Russia announced on Tuesday that it had begun testing an animal vaccine against the Corona virus, and hoped to find promising prototypes in June.
However, reaching a treatment may happen soon, as anti-viral treatment shows promising early results and is currently being tested before receiving approval from the regulatory authorities.
US President Donald Trump has urged scientists and drug companies to speed up the process, but experts say key constraints may not leave much margin for action.
H. wrote. Holden Thorpe, the editor of Science, in response to Trump’s calls, “The vaccine must have a fundamental scientific foundation. It must be capable of manufacture. It must be safe. It may take a year and a half or so much more.”
“The officials in the pharmaceutical industry have all the incentives to find a vaccine quickly, they will eventually sell it, but they also know that they cannot break the laws of nature to produce it,” he added.
The United States funds many pharmaceutical companies through the Department of Health and the National Institutes of Health.
The Coalition for Pandemic Preparation Innovations, a global organization headquartered in Oslo, also funds a number of companies, most of which are smaller partners who lack the capacity to mass-produce. So far, he has saved about $ 24 million.
Gilad Science Company
Of all the drugs associated with the virus that causes the Covid 19 pandemic, the Remediesfer vaccine, made by Gilad Science Company, may be the closest to market. It is not new but was developed to fight other viruses, including Ebola, and it has proven ineffective to fight it, and it has not yet been approved for any epidemic.
However, it has shown promising early results in the treatment of some emerging coronavirus patients in China, according to doctors, and the company is moving forward with final clinical trials in Asia known as “stage 3”. It has also been used to treat at least one American patient so far.
Anthony Fauci, of the National Institutes of Health and a leading government scientist who oversees the response to the Coruna virus, said it might be available in the “next few months.”
“There is only one drug that we think may have a real potency, and it is remedies,” said WHO official Bruce Aylward at a recent press conference in China.
Within the human body, remediesfer is changed to resemble one of four DNA blocks called nucleotides.
Newman told AFP that when the viruses copy themselves, they do so “quickly and randomly,” meaning that they may integrate this vaccine into their structure, knowing that human cells that are faster, do not make the same mistake.
And if the virus merges with the vaccine, then the drug adds mutations that can eliminate the virus.
Within weeks of Chinese researchers revealing the virus’s genome to the public, a team from the University of Texas at Austin managed to create a mirror model of its malignant protein, the part that clings to and damages human cells, and photographed with a chilled electron microscope.
This model now forms the basis for a possible vaccine because it may provoke an immune response in the human body without causing harm, the classic method of developing vaccines based on principles dating back to the smallpox vaccine in 1796.
The National Institutes of Health works with “Moderna”, a relatively new company launched in 2010, to make a vaccine using protein genetic information to grow into human muscle tissue instead of injecting into it.
This information is stored in a transient, intermediate material called “RNA messenger” that transmits the genetic code from DNA to cells.
The first human vaccine trial began on March 16, after it was proven to be effective in mice.
And if all goes well, the vaccine may be available in the market within about a year and a half, and ready in case the outbreak of the Corona virus continues until the next flu season, according to Fawsi.
Regenern last year developed a drug for intravenous infusion that showed a significant increase in survival rates among people with Ebola using what is known as “monoclonal antibiotics”.
To do this, scientists genetically modified mice to give them similar human immune systems. The company’s deputy head of research, Christos Keratosos, told AFP that the mice were exposed to viruses or to dilute forms of them to produce human antibiotics.
These antibiotics were isolated and examined to find the most effective ones for transplantation in laboratories, and for intravenous administration.
“If everything goes as planned, we should know what are the best antibiotics for the next few weeks,” with the start of human trials by the summer, said Keratosos.
The drug can work as a treatment and vaccine if given to people before they are exposed to the virus, although its effect will be temporary.
In the foreseeable future, the company is also trying to use its own medicines for other purposes using the same platform called “Kevzara” which has been approved to treat arthritis.
This can help combat acute pneumonia caused by Covid 19, in other words, it may fight a symptom instead of fighting the virus.
French pharmaceutical company Sanofi is cooperating with the United States government to use what is called a “recombinant DNA platform” to produce a possible vaccine.
This method allows taking the virus’s DNA and merging it with the DNA of a harmless virus, which happens while they may provoke an immune response, and then the antigens it produces can be increased.
This technology is the basis for the influenza vaccine developed by Sanofi and is believed to be well positioned in this race because of its SARS vaccine that provided partial protection to animals.
The company’s head of vaccine development, David Lowe, said Sanofi expects a potential vaccine to be ready for laboratory testing within six months and for clinical testing within a year and a half.
Innovio, another US drug company, has since its founding in the 1980s worked on DNA vaccines that work similarly to RNA vaccines but operate in a previous episode of the series.
For comparison, DNA can be considered as a reference book in a library, while RNA is like a copy of a page of this book that contains instructions for a task.
“We are planning to start human clinical trials in the United States in April and soon thereafter in China and South Korea where the outbreak affects a large percentage of people,” the company president and CEO, Joseph Joseph Kim, said in a statement.
“We are planning to provide 1 million doses by the end of the year with our current resources and capabilities,” he added.
Another remarkable effort
British pharmaceutical company GlaxoSmithKline teamed up with a Chinese biotechnology company to provide an auxiliary treatment technology.
Auxiliary treatment is added to some vaccines to enhance the immune response, thus providing stronger immunity and a longer anti-inflammatory period than the vaccine alone provides.
Like our director, CureFac is working with the University of Queensland on a DNA vaccine. The company’s CEO, Daniel Minichella, met White House officials earlier this month and announced that the company expects to produce a vaccine model within a few months.
And the American pharmaceutical company, “Johnson & Johnson”, is looking to use some of its medications for its non-primary purpose to treat the symptoms of patients infected with coronaviruses.
California-based Vert Biotechnology has isolated antibiotics from SARS survivors and is looking to see if it can be used to treat the emerging corona virus.